达芦那韦 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "达芦那韦" in Chinese language version.

Last modified: 03:49:30, 19 June 2026 (UTC)

Ref.Un. Ref.Website

Global rank Chinese rank

3413web.archive.org

1^st place

1914nih.gov

5^th place

3^rd place

122drugs.com

529^th place

229^th place

119doi.org

2^nd place

5^th place

81prezista.com

low place

44archive.org

6^th place

2^nd place

44semanticscholar.org

15^th place

141^st place

43fda.gov

470^th place

386^th place

22hivandhepatitis.com

low place

21europa.eu

62^nd place

150^th place

11purdue.edu

1,391^st place

1,746^th place

11hdl.handle.net

66^th place

243^rd place

archive.org (Global: 6^th place; Chinese: 2^nd place)

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Eron, J. HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 2000, 30: 160–170. PMID 10860901. doi:10.1086/313853 .

doi.org (Global: 2^nd place; Chinese: 5^th place)

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Leonis, G.; Czyznikowska, Z.; et al. Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps. J. Chem. Inf. Model. 2012, 52 (6): 1542–1558. PMID 22587384. doi:10.1021/ci300014z.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Lascar, R. M.; Benn, P. Role of darunavir in the management of HIV infection. HIV/AIDS: Research and Palliative Care. 2009, 1: 31–39. PMC 3218677 . PMID 22096377. doi:10.2147/hiv.s5397.
Li, D.; Zhang, Y.; et al. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J. Molecular Modeling. 2014, 20 (2): 2122. PMID 24526384. S2CID 23262721. doi:10.1007/s00894-014-2122-y.
McKeage, K; Perry, CM; Keam, SJ. Darunavir. Drugs. 2009, 69 (4): 477–503. PMID 19323590. doi:10.2165/00003495-200969040-00007.
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Liu, F.; Kovalevsky, A.Y. Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir. J. Mol. Biol. 2008, 381 (1): 102–115. PMC 2754059 . PMID 18597780. doi:10.1016/j.jmb.2008.05.062.
Eron, J. HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 2000, 30: 160–170. PMID 10860901. doi:10.1086/313853 .

drugs.com (Global: 529^th place; Chinese: 229^th place)

Darunavir. The American Society of Health-System Pharmacists. [2016-11-28]. （原始内容存档于2016-11-10）.
Darunavir (Prezista) Use During Pregnancy. Drugs.com. 2018-10-23 [2020-04-21]. （原始内容存档于2016-12-20）.

europa.eu (Global: 62^nd place; Chinese: 150^th place)

ema.europa.eu

Prezista EPAR. European Medicines Agency (EMA). [2020-04-21]. （原始内容存档于2019-06-25）. 本条目含有公有领域來源内容。

fda.gov (Global: 470^th place; Chinese: 386^th place)

fda.gov

FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs. U.S. Food and Drug Administration (FDA) (新闻稿). [2016-11-10]. （原始内容存档于2016-11-13）.
HIV/AIDS Historical Time Line 2000 - 2010. U.S. Food and Drug Administration. 2018-01-05 [2020-04-21]. （原始内容存档于2019-06-01）.

accessdata.fda.gov

Drug Approval Package: Prezista (Darumavir) NDA #021976. U.S. Food and Drug Administration (FDA). 2006-09-06 [2020-04-21]. （原始内容存档于2016-07-01）.

hdl.handle.net (Global: 66^th place; Chinese: 243^rd place)

World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

hivandhepatitis.com (Global: low place; Chinese: low place)

hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial, 2008-10-28, URL 互联网档案馆的存檔，存档日期2009-07-19..
hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Darunavir (Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive Patients, Caution Urged for Pregnant Women, 2008-10-24, URL 互联网档案馆的存檔，存档日期2009-05-19..

nih.gov (Global: 5^th place; Chinese: 3^rd place)

ncbi.nlm.nih.gov

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Leonis, G.; Czyznikowska, Z.; et al. Computational Studies of Darunavir into HIV-1 Protease and DMPC Bilayer: Necessary Conditions for Effective Binding and the Role of the Flaps. J. Chem. Inf. Model. 2012, 52 (6): 1542–1558. PMID 22587384. doi:10.1021/ci300014z.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Lefebvre, E.; Schiffer, C. A. Resilience to Resistance of HIV-1 Protease Inhibitors: Profile of Darunavir. AIDS Rev. 2008, 10 (3): 131–142. PMC 2699666 . PMID 18820715.
Lascar, R. M.; Benn, P. Role of darunavir in the management of HIV infection. HIV/AIDS: Research and Palliative Care. 2009, 1: 31–39. PMC 3218677 . PMID 22096377. doi:10.2147/hiv.s5397.
Li, D.; Zhang, Y.; et al. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J. Molecular Modeling. 2014, 20 (2): 2122. PMID 24526384. S2CID 23262721. doi:10.1007/s00894-014-2122-y.
McKeage, K; Perry, CM; Keam, SJ. Darunavir. Drugs. 2009, 69 (4): 477–503. PMID 19323590. doi:10.2165/00003495-200969040-00007.
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
Liu, F.; Kovalevsky, A.Y. Effect of Flap Mutations on Structure of HIV-1 Protease and Inhibition by Saquinavir and Darunavir. J. Mol. Biol. 2008, 381 (1): 102–115. PMC 2754059 . PMID 18597780. doi:10.1016/j.jmb.2008.05.062.
Eron, J. HIV-1 Protease Inhibitors. Clinical Infectious Diseases. 2000, 30: 160–170. PMID 10860901. doi:10.1086/313853 .

aidsinfo.nih.gov

Darunavir / Cobicistat. AIDSinfo. U.S. Department of Health and Human Services. [2018-06-29]. （原始内容存档于2020-03-03）.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (PDF). Department of Health and Human Services. 2019-12-18 [2020-04-21]. （原始内容 (PDF)存档于2020-08-13）. 简明摘要.

dailymed.nlm.nih.gov

Prezista- darunavir tablet, film coated Prezista- darunavir suspension. DailyMed. 2019-06-06 [2020-04-21]. （原始内容存档于2019-02-06）.

files.aidsinfo.nih.gov

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (PDF). Department of Health and Human Services. 2019-12-18 [2020-04-21]. （原始内容 (PDF)存档于2020-08-13）. 简明摘要.

prezista.com (Global: low place; Chinese: low place)

Drug Monograph, Prezista. （原始内容存档于2016-11-11）.

purdue.edu (Global: 1,391^st place; Chinese: 1,746^th place)

chem.purdue.edu

HIV/AIDS Research. Purdue Chemistry: The Ghosh Laboratory. [2021-06-24]. （原始内容存档于2021-06-24）.

semanticscholar.org (Global: 15^th place; Chinese: 141^st place)

api.semanticscholar.org

MacArthur, Rodger. Darunavir: Promising Initial Results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.
King, N. M.; Prabu-Jeyabalan, M.; et al. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor. Journal of Virology. 2004, 78 (21): 12012–21. PMC 523255 . PMID 15479840. S2CID 828919. doi:10.1128/JVI.78.21.12012-12021.2004 .
Li, D.; Zhang, Y.; et al. Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation. J. Molecular Modeling. 2014, 20 (2): 2122. PMID 24526384. S2CID 23262721. doi:10.1007/s00894-014-2122-y.
MacArthur, Rodger D. Darunavir: promising initial results. The Lancet. 2007, 369 (9568): 1143–1144. PMID 17416241. S2CID 31175809. doi:10.1016/S0140-6736(07)60499-1.

web.archive.org (Global: 1^st place; Chinese: 1^st place)

Darunavir. The American Society of Health-System Pharmacists. [2016-11-28]. （原始内容存档于2016-11-10）.
Darunavir (Prezista) Use During Pregnancy. Drugs.com. 2018-10-23 [2020-04-21]. （原始内容存档于2016-12-20）.
Prezista- darunavir tablet, film coated Prezista- darunavir suspension. DailyMed. 2019-06-06 [2020-04-21]. （原始内容存档于2019-02-06）.
HIV/AIDS Research. Purdue Chemistry: The Ghosh Laboratory. [2021-06-24]. （原始内容存档于2021-06-24）.
Darunavir / Cobicistat. AIDSinfo. U.S. Department of Health and Human Services. [2018-06-29]. （原始内容存档于2020-03-03）.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (PDF). Department of Health and Human Services. 2019-12-18 [2020-04-21]. （原始内容 (PDF)存档于2020-08-13）. 简明摘要.
hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Efficacy and Safety of Boosted Darunavir (Prezista) Are Superior to Lopinavir/ritonavir (Kaletra) at 96 Weeks: ARTEMIS Trial, 2008-10-28, URL 互联网档案馆的存檔，存档日期2009-07-19..
hivandhepatitis.com 互联网档案馆的存檔，存档日期2007-07-13., Darunavir (Prezista) Receives Full Traditional Approval, Dose Set for Treatment-naive Patients, Caution Urged for Pregnant Women, 2008-10-24, URL 互联网档案馆的存檔，存档日期2009-05-19..
Drug Monograph, Prezista. （原始内容存档于2016-11-11）.
Prezista EPAR. European Medicines Agency (EMA). [2020-04-21]. （原始内容存档于2019-06-25）. 本条目含有公有领域來源内容。
FDA Approves New HIV Treatment for Patients Who Do Not Respond to Existing Drugs. U.S. Food and Drug Administration (FDA) (新闻稿). [2016-11-10]. （原始内容存档于2016-11-13）.
HIV/AIDS Historical Time Line 2000 - 2010. U.S. Food and Drug Administration. 2018-01-05 [2020-04-21]. （原始内容存档于2019-06-01）.
Drug Approval Package: Prezista (Darumavir) NDA #021976. U.S. Food and Drug Administration (FDA). 2006-09-06 [2020-04-21]. （原始内容存档于2016-07-01）.

达芦那韦 (Chinese Wikipedia)

archive.org (Global: 6th place; Chinese: 2nd place)

doi.org (Global: 2nd place; Chinese: 5th place)

drugs.com (Global: 529th place; Chinese: 229th place)

europa.eu (Global: 62nd place; Chinese: 150th place)